Publicacións en colaboración con investigadores/as de Hospital Virgen de la Arrixaca (18)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  4. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  5. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

  2. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802

  3. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2707-2717

2022

  1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  2. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. Correction to: SEOM clinical guidelines for anaemia treatment in cancer patients (2020) (Clinical and Translational Oncology, (2021), 23, 5, (931-939), 10.1007/s12094-021-02580-2)

    Clinical and Translational Oncology

  2. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  3. SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 931-939

2019

  1. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer

    Thrombosis and Haemostasis, Vol. 119, Núm. 11, pp. 1849-1859

2018

  1. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

    BMC Pharmacology and Toxicology, Vol. 19, Núm. 1

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

2006

  1. Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome

    Transplant Immunology, Vol. 17, Núm. 1, pp. 43-46

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051